Cellceutix Corporation (CTIX.OB) Pursuing Multi-Billion Dollar Psoriasis Treatment Market; Company Continues Push to Develop Compounds
Cellceutix Corporation is not a company standing still. The emerging biotech has 8 compounds in their portfolio, with two of them being actively developed by the Company. Kevetrin, Cellceutix’s lead compound is in development for the treatment of multi-drug resistant cancers and is rapidly approaching human trials as the IND filing with the FDA is being prepared. KM-391 has already garnered industry attention as it is being developed to address the core issues of autism. Constantly moving forward, Cellceutix announced in late July that they have retained Destum Partners to identify and secure a developmental partner for another very promising…